A preventive strategy targeting the NLRP3 inflammasome at an early stage holds potential benefits, necessitating future large-scale prospective studies to validate colchicine’s effect on diabetes risk reduction by monitoring inflammatory parameters and insulin sensitivity. This evidence concerns the gene INS and diabetes mellitus.